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Neuroblastoma, a pediatric tumor of the sympathetic nervous system, is predominantly driven by copy
number aberrations, which predict survival outcome in global neuroblastoma cohorts and in low-risk cases.
For high-risk patients there is still a need for better prognostic biomarkers. Via an international
collaboration, we collected copy number proﬁles of 556 high-risk neuroblastomas generated on different
array platforms. This manuscript describes the composition of the dataset, the methods used to process the
data, including segmentation and aberration calling, and data validation. t-SNE analysis shows that samples
cluster according to MYCN status, and shows a difference between array platforms. 97.3% of samples are
characterized by the presence of segmental aberrations, in regions frequently affected in neuroblastoma.
Focal aberrations affect genes known to be involved in neuroblastoma, such as ALK and LIN28B. To
conclude, we compiled a unique large copy number dataset of high-risk neuroblastoma tumors, available
via R2 and a Shiny web application. The availability of patient survival data allows to further investigate the
prognostic value of copy number aberrations.
Design Type(s) disease outcome analysis objective • data analysis objective
Measurement Type(s) copy number variation
Technology Type(s) digital curation
Factor Type(s) survival
Sample Characteristic(s) Homo sapiens • neuroblastoma
1Center for Medical Genetics, Ghent University, Ghent, Belgium. 2Cancer Research Institute Ghent (CRIG), Ghent
University, Ghent, Belgium. 3Department of Oncogenomics, Academic Medical Center, University of Amsterdam,
Amsterdam, The Netherlands. 4Institut Cochin, Inserm U1016, CNRS UMR 8104, Université Paris Descartes UMR-
S1016, F-75014 Paris, France. 5Institut Curie, Inserm U900, Mines ParisTech, PSL Research University, F-75005
Paris, France. 6Department of Human Genetics, McGill University, Montreal, Quebec, Canada. 7Recherche
Translationelle en Oncologie Pédiatrique (RTOP) and Department of Pediatric Oncology, Institut Curie, Paris,
France. 8U830, INSERM, Paris, France. Correspondence and requests for materials should be addressed to K.D.P.
(email: katleen.depreter@ugent.be)
OPEN
Received: 19 March 2018
Accepted: 10 September 2018
Published: 30 October 2018
www.nature.com/scientificdata
SCIENTIFIC DATA | 5:180240 | DOI: 10.1038/sdata.2018.240 1
Background & Summary
Neuroblastoma is a pediatric tumor of the sympathetic nervous system, affecting mainly children under
the age of ﬁve years1. It is the most common extracranial solid cancer, making up 5% of childhood cancer
diagnoses, while accounting for approximately 10% of childhood cancer deaths2,3.
Neuroblastoma is characterized by extensive clinical heterogeneity, illustrated by different clinical
evolutions ranging from spontaneous regression to aggressive disease. Risk stratiﬁcation of
neuroblastoma patients is based on clinical parameters, histopathological parameters and genetic
parameters including MYCN ampliﬁcation, 11q loss and the global copy number proﬁle4,5.
While recurrent single nucleotide mutations, such as those targeting ALK and ATRX, are observed
infrequently at diagnosis6,7, copy number aberrations occur at much higher frequency and are strongly
associated with disease outcome. Tumors with only numerical aberrations have a favorable prognosis,
while the presence of at least one segmental aberration is indicative of poor survival outcome8.
Neuroblastoma is a rare disease, therefore it is challenging to collect enough tumor material and data
for a sufﬁciently powered study. Within the Ultra-High-Risk (UHR) working group of the International
Neuroblastoma Response Criteria (INRC) consortium5, we collected DNA copy number proﬁles and
clinical data of 556 high-risk neuroblastoma patients, resulting in a unique dataset. The aim of this
project was to explore whether speciﬁc (combinations of) segmental DNA copy number aberrations allow
to better discriminate high-risk patients with fatal outcome from high-risk patients with favorable
outcome9.
The collected copy number proﬁles were generated on several aCGH and SNP array platforms. The
data were uniformized by converting to the same genome build hg19, and by segmenting with the same
method (summarized in Fig. 1). From the segmented data, aberrations were called using speciﬁc cutoffs
for each array platform. Exploration of the collected and processed data conﬁrmed the presence of
segmental and focal aberrations in regions frequently affected in neuroblastoma and that samples cluster
according to MYCN status rather than platform and inter-laboratory differences.
In this data descriptor, we describe in detail the composition of the data with respect to sample
inclusion criteria and clinical characteristics and the methods used to process the data. We provide access
to normalized probe-level data and segmented data as well as instructions to analyze and visualize the
data using either the R2 platform10, the statistical programming language R or a Shiny web application.
Methods
DNA copy number data collection
Copy number proﬁling data from 556 primary neuroblastoma tumors were collected through the
UltraHigh-Risk (UHR) working group of the International Neuroblastoma Response Criteria (INRC)
consortium. These tumors originated from high-risk patients enrolled in the SIOPEN, GPOH, COG or
Japanese treatment protocol (SIOPEN: European Society for Paediatric Oncology Neuroblastoma,
GPOH: Society for Paediatric Oncology and Haematology, COG: Children’s Oncology Group).
Published6,11,12 and unpublished copy number proﬁling data generated on different platforms including
aCGH arrays from Agilent (resolution ranging from 44k-1M) and NimbleGen (72k) and SNP arrays
from Affymetrix (250k and 2.6 M) and Illumina (550k) were included in this study. Initially, data from
671 high-risk samples were collected, with high-risk deﬁned as either stage 4 and older than 1 year, or
MYCN-ampliﬁed (any age and stage). MYCN ampliﬁcation status was determined by FISH or qPCR. Of
the 671 samples, 16 samples were discarded due to bad quality proﬁles and 98 samples were discarded
due to suspected contamination with normal cells (49 silent proﬁles without detected copy number
aberrations and 50 with almost undetectable aberrations), resulting in a set of 556 samples. Sample
annotations, including among others age at diagnosis, disease stage, MYCN status and overall and event-
free survival, are available at Figshare (Table 1: Patient annotations, Data Citation 1). However, event-free
survival data are not available for the Japanese dataset. This collection strategy has been reported already
in the Supplementary Methods of the research paper originally related to this dataset9. The patient
annotations in this publication are the same as Supplementary Table 1 in the related paper9.
DNA copy number data processing
The processing steps performed on the collected data to obtain segmented copy number data is
summarized in Fig. 1. Raw or normalized copy number data were collected. Raw data were median-
normalized. When necessary, chromosomal coordinates were converted from genome build hg17 or hg18
to genome build hg19 using the “liftOver” function from the R package “rtracklayer”. Only for the COG
cohort (Illumina platform), instead of using liftOver, we replaced the probe positions with hg19 positions
downloaded from the Illumina website. These normalized, hg19 probe-level copy number data are
available at GEO with accession number GSE103123 (Data Citation 2). An overview of the processing
steps applied to each of the collected datasets to obtain the data available at GEO is available at Figshare
(Table 2: data processing steps, Data Citation 1). Starting from the normalized hg19 data, segmentation of
the copy number proﬁles was done using SegAnnDB13 (http://seganndb.genap.ca/, a video with
instructions can be found on the website). This is an interactive web-based tool that combines
mathematical modelling with visual annotation to call aberrations, ensuring qualitative breakpoint calling
for the majority of samples. Aberrations that were abundantly present across samples proﬁled on a
certain platform were considered as artefacts (usually also a high variability in probe copy number value
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was observed for these regions) and ignored in the segmentation process. Due to the semi-automatic
nature, not all aberrations are detected by this tool, e.g. subclonal aberrations might be missed. Only copy
number data were used as input for the segmentation as allele ratios were available only for a limited
number of samples. As not for all copy number proﬁling experiments gender-matched controls were
used, data from chromosome Y were omitted. The segmented copy number proﬁles were downloaded
from the SegAnnDB server for further analysis and are available at Figshare (Table 3: Segmented copy
number data, Data Citation 1). A shorter version of these processing methods are included in the
(Supplementary) Methods section of the related paper9.
Deﬁning cutoffs to call aberrations
Histograms of the segment log2 ratios for each array platform reveal that their distribution is dependent
on the array platform. More speciﬁcally, aCGH arrays generate log2 ratios with a higher dynamic range
than SNP arrays (Fig. 2). Based on this observation, gains and losses were called using platform-speciﬁc
cutoffs. Following cutoffs were used for gains/losses respectively: +0.15/-0.25 for SNP arrays (Affymetrix
and Illumina), and +0.2/-0.3 for aCGH arrays (Agilent and NimbleGen), represented by the vertical lines
in Fig. 2. Also for calling of ampliﬁcations platform-speciﬁc cutoffs were used. We compared copy
number values (log2 ratio) of segments encompassing MYCN for MYCN-ampliﬁed and nonampliﬁed
samples (as determined based on FISH/qPCR analyses) (Fig. 3). Cutoffs were chosen to maximize
discrimination between MYCN-ampliﬁed and nonampliﬁed samples and exclude high-level gains: 1.5 for
Affymetrix and NimbleGen arrays, 2 for Agilent arrays and 0.7 for Illumina arrays. Finally, segments with
log2 ratio lower than -2 were called as homozygous deletion. This computational method using cutoffs
generates a good general view of the aberrations present in the study population, but occasionally misses
some aberrations, e.g. subclonal aberrations will typically not reach the cutoff. The resulting annotations
are included in the segmented data available at Figshare (Table 3: Segmented copy number data, Data
Citation 1). This paragraph is a more elaborate version of the procedure described in the related paper9.
Presence of segmental aberrations of frequently affected chromosome arms
For each patient, we determined the presence of aberrations in any of the frequently affected
chromosome arms, namely loss of 1p, 3p, 4p, 11q and 14q, and gain of 1q, 2p and 17q. Aberrations of
(partial) chromosome arms were deﬁned as gains and losses larger than 3Mb, hereby excluding whole
chromosome aberrations and ampliﬁcations. In case of aberrations spanning the centromere, the
aberration is considered to be on the p arm if the part on p is longer and vice versa. Note that this is a
computational scoring generating a general image of abundance of aberrations, not aiming to establish a
detailed genomic proﬁle for individual patients. The resulting annotations are included in the patient
annotations available at Figshare (Table 1: Patient annotations, Data Citation 1). This procedure is also
described in the Supplementary Methods of the related paper9.
Code availability
The code to analyze or visualize the data in R can be found on GitHub (https://github.com/padpuydt/
copynumber_HR_NB/). See Usage Notes for more information.
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Figure 1. Overview of copy number data processing of 556 high-risk primary neuroblastoma tumors from
probe-level to segmented data. Raw/normalized probe-level data were converted to hg19 genome build using
liftOver, followed by median normalization and segmentation using SegAnnDB. Data are available in Gene
Expression Omnibus (GEO). Segmented data are available in Table 3.
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Data Records
All tables are available at ﬁgshare (Data Citation 1). Clinical and genomic information of the patients
(Table 1: Patient annotations, Data Citation 1) include age at diagnosis, disease stage, and overall and
event-free survival, MYCN status and the presence of segmental aberrations of chromosome arms
frequently affected in neuroblastoma, such as 1p loss and 2p gain. Normalized probe-level copy number
data using genome build hg19 can be accessed through GEO, with accession number GSE103123 (Data
Citation 2). An overview is provided of the processing steps that were performed on the collected data to
obtain the data that is available on GEO (Table 2: data processing steps, Data Citation 1), as well as
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Figure 2. Histogram of log2 ratios of segments from all samples, according to platform. Cutoffs are
determined based on intersecting yellow curves (normal segments) with blue or red curves (lost/gained
segments). For SNP arrays (left) lower cutoffs are used compared to aCGH platforms (right) to call copy number
aberrations. Figure adapted from Supplementary Figure 1 in related paper9.
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Figure 3. Comparison of MYCN copy number log2 ratios in MYCN-ampliﬁed and non-ampliﬁed cases,
according to platform. MYCN log2 ratios of MYCN-ampliﬁed cases are lower for SNP arrays than aCGH
arrays, justifying platform-speciﬁc cutoffs to call ampliﬁcations. Figure adapted from Supplementary Figure 10
in related paper9.
www.nature.com/sdata/
SCIENTIFIC DATA | 5:180240 | DOI: 10.1038/sdata.2018.240 4
lab
cog (n=207)
col (n=58)
fr-clb (n=20)
fr-ic (n=53)
gh (n=102)
it (n=24)
jap (n=68)
sp (n=8)
vi (n=16)
Tumor Neuroblastoma HR - Preter - 556
T-SNE (perplexity=30)
-15
-10
-5
0
5
10
15
-25 -20 -15 -10 -5 0 5 10 15 20 25
V
2
V1
platform
affymetrix (n=84)*
agilent (n=204)
illumina (n=215)*
nimblegen (n=53)
-15
-10
-5
0
5
10
15
-25 -20 -15 -10 -5 0 5 10 15 20 25
V
2
V1
mycn
amp (n=255)
non_amp (n=301)
-15
-10
-5
0
5
10
15
-25 -20 -15 -10 -5 0 5 10 15 20 25
V
2
V1
numerical
segmental (n=542)
whole_chrom (n=14)
-15
-10
-5
0
5
10
15
-25 -20 -15 -10 -5 0 5 10 15 20 25
V
2
V1
age_cat
1-1.5y (n=45)
<1y (n=24)
>1.5y (n=485)
na (n=2)
-15
-10
-5
0
5
10
15
-25 -20 -15 -10 -5 0 5 10 15 20 25
V
2
V1
stage
na (n=3)
st1 (n=2)
st2a (n=3)
st2b (n=2)
st3 (n=28)
st4 (n=515)
st4s (n=3)
-15
-10
-5
0
5
10
15
-25 -20 -15 -10 -5 0 5 10 15 20 25
V
2
V1
*SNP
a b
f
dc
e
Figure 4. t-SNE analysis illustrating clustering of samples. Samples are colored according to genomic (top),
clinical (middle) and technical (bottom) variables, indicating that technical bias is limited to variable dynamic
ranges among platforms and that samples cluster according to MYCN status. cog: Children’s Oncology Group,
USA; fr-clb: Centre Léon Bérard, France; fr-ic: Institut Curie, France; gh: Ghent, Belgium; it: Genova, Italy; jap:
Chiba, Japan; sp: Valencia, Spain; col: Cologne, Germany; vi: Vienna, Austria.
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segmented copy number data (Table 3: Segmented copy number data, Data Citation 1), in which the
column “annotation” reports on the presence of an aberration considering the platform-speciﬁc cutoffs
(see Methods).
Technical Validation
Bias
To check for possible bias, we performed t-SNE analysis using the R2 platform10, for several genomic
(top), clinical (middle) and technical (bottom) variables (Fig. 4). This analysis reveals a clear clustering of
samples according to MYCN status (Fig. 4a). Samples with only numerical aberrations are somewhat
clustering together and situated in between the MYCN-ampliﬁed and MYCN-nonampliﬁed group (Fig.
4b). Samples slightly cluster according to the clinical variables age at diagnosis (in three categories) and
stage of the disease, but this mainly reﬂects the fact that young ( o 1 year) and non-stage 4 patients were
only included in the study when presenting with MYCN ampliﬁcation (Fig. 4c and d). In Fig. 4e, a slight
bias is observed for different array platforms, with samples analyzed on CGH arrays (especially Agilent)
being on the outer rim, and samples analyzed on SNP arrays (especially Illumina) situated closer to the
center. This can be explained by the fact that CGH arrays generate copy number log2 ratios with a higher
dynamic range than SNP arrays, as also observed in the histograms in Fig. 2. This effect is demonstrated
in the simulations by Wattenberg et al. (section 6)14 . In Fig. 4f, we demonstrate that there is no bias
across labs that use the same platform.
Detection of typical segmental and focal aberrations
Of the 556 collected high-risk samples, 97.3% contain segmental aberrations, corresponding to regions
frequently affected in neuroblastoma. The heatmap of chromosomal gains and losses of all tumors (Fig. 5)
clearly shows recurrent loss of 1p, 3p, 4p, and 11q and recurrent gain of 1q, 2p, 7 and 17q. This
visualization conﬁrms previous reports15 that most tumors with MYCN ampliﬁcation also have 1p loss
and 17q gain and that many tumors with 11q loss also present with 3p loss and 17q gain. A frequency
Sa
m
pl
es
Chromosomes
M
N
A
no
n-
M
N
A
W
CA
loss gain
Figure 5. Copy number aberrations in all samples. Heatmap of aberrations in each individual sample,
illustrating patterns of co-occurring aberrations, e.g. 11q and 3p loss, or MYCN ampliﬁcation (MNA) and 1p
deletion. WCA: whole-chromosome aberrations. Figure adapted from Supplementary Figure 5 in related paper9.
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plot of the gains and losses can be found in Fig. 1b of the related research paper9. Next to larger segmental
aberrations, also focal (o5Mb) aberrations were observed that have previously been described in
neuroblastoma, including focal gains or ampliﬁcations of ALK and LIN28B.
Detection of ampliﬁcations
In order to set a good cut-off to determine ampliﬁcations, log2 copy number ratios of the MYCN locus
were compared in samples with or without MYCN ampliﬁcation according to FISH and qPCR. This
analysis (Fig. 3) reveals that the dynamic range of log2 ratios is highly variable between platforms and
suggests that cutoffs used to call ampliﬁcations should be determined per platform. Using these cutoffs we
can correctly determine MYCN ampliﬁcation status (as previously established by FISH/qPCR) in 97% of
Affymetrix samples, 95% of Illumina samples, 99% of Agilent samples and 100% of NimbleGen samples.
As described in the related paper9 and by Curtis et al.16, detection of ampliﬁcations is more cumbersome
in data from Illumina platforms and should be interpreted with caution.
Usage Notes
Probe-level data can be accessed at GEO with the accession number GSE103123 (Data Citation 2).
Sample annotations are provided in the GEO series metadata and at Figshare (Table 1: Patient
annotations, Data Citation 1). Instead of downloading probe-level data, it is also possible to directly use
the segmented data, also available at Figshare (Table 3: Segmented copy number data, Data Citation 1).
The segmented proﬁles have been manually inspected to ensure conﬁdence of the called aberrations. The
column “annotation” represents the presence of an aberration considering the platform-speciﬁc cutoffs
(see Methods for details), but also the segment log2 ratios can be used.
Data can be analyzed and visualized using either the R statistical program, the R2 web-based
platform10, or a Shiny web application17. For R users we recommend the R package “copynumber”18,
which provides functions for visualization, including frequency plots and heatmaps with chromosome
ideograms. The R package CNTools19 can be used to transform the segmented data into a window- or
Figure 6. R2 platform: examples of data exploration and visualization. (a) Copy number values of CHD5
(1p36.31), comparing samples with MYCN ampliﬁcation (left) and without MYCN ampliﬁcation (right). Other
sample annotations including age at diagnosis can be read in the heatmap below the plot. (b) Comparing
occurrence of two tracks, illustrating that 11q and 3p loss signiﬁcantly co-occur. (c) Genome browser zooming
in on a sample with ampliﬁcations for ODC1 (left ampliﬁed region) and MYCN (right ampliﬁed region).
(d) Kaplan-Meier analysis comparing survival of cases with and without 6q loss.
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gene-based matrix. A script is provided on GitHub, including functions to select samples with an
aberration for a certain gene/region (https://github.com/padpuydt/copynumber_HR_NB/).
Using the R2 platform10, one can perform multiple data analysis procedures and create several types of
plots. A few examples are plotting a gene’s copy number in groups of samples, associations between
sample annotations, survival analysis and viewing samples in the genome browser (Fig. 6). To create
these plots, go to the dataset home page on R2 (https://hgserver1.amc.nl/cgi-bin/r2/main.cgi?
&dscope=NB556HR&option= about_dscope). The R2 genome browser is directly linked there. The
other three analyses/plots can be found under “Other Analyses”. There we selected “View a gene in
groups”, “Relate 2 tracks” and “Kaplan Meier by annotated parameter” in step 3 (Select type of analysis).
In addition, R2 allows to perform correlation analysis between genes, ﬁnd genes with differential copy
number between groups, perform dimensionality reduction with t-SNE maps, or generate a heatmap of a
speciﬁc (grouped) subset of samples (CGH Sample Sorter on dataset home page). More detailed
documentation can be found on the R2 website (http://r2.amc.nl).
Finally, we developed a Shiny web application17 to interrogate the copy number status and association
with survival of any gene or genomic region of interest. After ﬁlling in the gene name or cytoband, the
samples with an aberration overlapping with that region will be plotted in a heatmap. One can also plot
survival curves of samples with versus without an aberration in the region of interest. A preliminary
version can be accessed through https://padpuydt.shinyapps.io/check_cn_in_hr_nb/.
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